IP Library Granted Patent US 9,403,895
Granted Patent B2
US 9,403,895 · App. 14/700,951 · Granted Aug 2, 2016

Production and delivery of a stable collagen

Inventors: M. Peter Marinkovich (Redwood City, CA); Alfred T. Lane (Los Altos, CA); Jayakumar Rajadas (Cupertino, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; The United States of America as Represented by the Department of Veterans Affairs
C07K14/78A61K38/39A61M37/0015A61M2037/0023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,403,895
App. No.
14/700,951
Granted
Aug 2, 2016
Kind
B2
Abstract

Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.

Claims (11)

1. A method of delivering collagen VII to the dermal layer of skin, the method comprising:

fabricating an array of biodegradable microneedles comprising collagen VII incorporated into the microneedles; and

contacting the skin of an individual with said array with a pressure sufficient to penetrate the skin to the depth of anchoring fibrils.

2. The method of claim 1 , wherein the method further comprises:

producing collagen VII for incorporation into the microneedles, by synthesizing recombinant collagen VII in a host cell that has been genetically modified to increase expression of prolyl-4-hydroxylase.

3. The method of claim 2 , wherein said individual suffers from epidermolysis bullosa.

4. An array of biodegradable microneedles, wherein said microneedles comprise collagen VII incorporated into the microneedles.

5. The array of claim 4 , wherein said collagen VII is produced by the method of synthesizing recombinant collagen VII in a host cell that has been genetically modified to increase expression of prolyl-4-hydroxylase;

wherein recombinantly produced collagen VII has increased stability relative to a collagen produced in a comparable host cell lacking said genetic modification.

6. The method of claim 1 , wherein the microneedles are comprised of alginate or chitosan mixed with Collagen VII.

7. The array of claim 4 , wherein the microneedles are comprised of alginate or chitosan mixed with Collagen VII.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2015
From: MARINKOVICH, M. PETER
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 036331/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2015
From: LANE, ALFRED T.; RAJADAS, JAYAKUMAR
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 036075/0068 →
CONFIRMATORY LICENSE Recorded May 18, 2015
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035706/0333 →
Continuity (3)
Continuation 14112444
Provisional Application 61479068 · Apr 26, 2011
Related Publication 20150232535A1 · Aug 20, 2015